533 related articles for article (PubMed ID: 20178404)
1. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Faraone SV; Glatt SJ
J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective.
Lachaine J; Beauchemin C; Sasane R; Hodgkins PS
Postgrad Med; 2012 May; 124(3):139-48. PubMed ID: 22691908
[TBL] [Abstract][Full Text] [Related]
4. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program.
Lawson KA; Johnsrud M; Hodgkins P; Sasané R; Crismon ML
Clin Ther; 2012 Apr; 34(4):944-956.e4. PubMed ID: 22444786
[TBL] [Abstract][Full Text] [Related]
5. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
Barner JC; Khoza S; Oladapo A
Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
[TBL] [Abstract][Full Text] [Related]
7. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
[TBL] [Abstract][Full Text] [Related]
9. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
10. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu E; Erder MH
J Med Econ; 2013 Oct; 16(10):1203-15. PubMed ID: 23937642
[TBL] [Abstract][Full Text] [Related]
11. Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder.
Van Brunt DL; Johnston JA; Ye W; Pohl GM; Sun PJ; Sterling KL; Davis ME
Pharmacotherapy; 2005 Nov; 25(11):1541-9. PubMed ID: 16232017
[TBL] [Abstract][Full Text] [Related]
12. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
13. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
Marcus SC; Wan GJ; Kemner JE; Olfson M
Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
[TBL] [Abstract][Full Text] [Related]
14. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
15. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.
Setyawan J; Guérin A; Hodgkins P; Gauthier G; Cloutier M; Wu E; Erder MH
J Med Econ; 2013 Nov; 16(11):1275-89. PubMed ID: 24004347
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy with atomoxetine for US children and adolescents.
Bhatara VS; Aparasu RR
Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019
[TBL] [Abstract][Full Text] [Related]
18. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments.
Stein MA
Am J Manag Care; 2004 Jul; 10(4 Suppl):S89-98. PubMed ID: 15352535
[TBL] [Abstract][Full Text] [Related]
19. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.
Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu EQ; Erder MH
J Med Econ; 2013 Jul; 16(7):962-75. PubMed ID: 23621503
[TBL] [Abstract][Full Text] [Related]
20. Review of medication adherence in children and adults with ADHD.
Adler LD; Nierenberg AA
Postgrad Med; 2010 Jan; 122(1):184-91. PubMed ID: 20107302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
